Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.
The RECOURSE trial of the combined oral drugs trifluridine and tipiracil hydrochloride (TAS-102) is a global, randomized, double blind, placebo-controlled study of 800 people with refractory mCRC. Each participant had received at least two prior failed treatment attempts using standard chemotherapy and received either TAS-102 or placebo to establish the efficacy and toleration of the drug combination and improve overall survival.
“We are very pleased by the results from the phase 3 RECOURSE trial in refractory mCRC, which support TAS-102 as a potential new treatment option for this patient population,” Fabio M. Benedetti, MD, senior vice president and chief medical officer at Taiho Oncology, said in a press release.
Report: http://bit.ly/1hK7lQD
Source: Healio
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More